ReviewGastroenterology research2026
Acyl-CoA Synthetase Long-Chain Family Member 4 in Liver Injury: Multidimensional Regulation and Therapeutic Potential.
Review in Gastroenterology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acyl-CoA synthetase long-chain family member 4 (ACSL4) is a key enzyme that catalyzes the conjugation of long-chain fatty acids with coenzyme A to form acyl-CoA, showing particularly high specificity for polyunsaturated fatty acids. In recent years, ACSL4 has gained increasing attention for its central role in various liver diseases, including metabolic dysfunction-associated steatotic liver disease, liver fibrosis, hepatocellular carcinoma, and ferroptosis. This article systematically elaborates on the expression profiles and localization of ACSL4 in different liver cell types, as well as its multidimensional regulatory mechanisms in liver injury and the pathogenesis of related diseases. In addition, it explores the potential therapeutic prospects of targeting ACSL4.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.